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SUMMARY
Schistosoma japonicum,Fasciola hepatica andF. gigantica are digenetic trematodes and, therefore, possess similar life cycles.
While schistosomiasis japonica has for a long time been recognised as amajor disease of both humans and animals, infection
with fasciolids has only been considered of relevance to animals. However, a number of recent reports indicate that
fasciolosis is becoming a serious public health problem, especially in South America, Egypt and Iran (sporadic cases are
also on the increase throughout Europe). Vaccines targeted at animals could play an important role in controlling these
three diseases in animals and, by blocking transmission of infection, have a concurrent beneﬁcial eﬀect on disease in
humans. Approaches towards identifying and producing vaccines against these parasites are similar and are discussed
in this reveiw.
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INTRODUCTION
This review focuses on the digenetic trematodes
Schistosoma japonicum, Fasciola hepatica and
F. gigantica as each is an important zoonosis of man,
particularly in Asia. Vaccines against S. mansoni
have been reviewed extensively elsewhere (Pearce,
2003; Bergquist, Leonardo and Mitchell, 2005;
Capron et al. 2005). Because of their relatedness
and similarities in life cycle the reader will notice
a clear parallel in the approaches taken towards
vaccine development (choice of antigens, technology
to produce vaccines etc.) for each of these parasites.
In addition, the concept of producing a transmission
blocking vaccine, i.e. one that lowers the level of
parasites in the environment and thus prevents in-
fection to other animals and humans, has been sug-
gested as an important component of disease control
(Dalton et al. 1996; Williams et al. 2002). This is
particularly pertinent as in some regions, Asia and
Egypt in particular, where both schistosomiasis and
fasciolosis are endemic in animals and/or humans
and, therefore, disease control programmes will need
to take both into account.
VACCINES AGAINST SCHISTOSOMA
JAPONICUM
Over 250 million people and signiﬁcant numbers
of domestic livestock animals are infected and
280000 individuals die as a direct result of schisto-
somiasis infection in sub-Saharan Africa alone an-
nually (van der Werf et al. 2003). A recent important
article by King, Dickman and Tisch (2005) indicates
that, in terms of morbidity and mortality, schisto-
somiasis represents an even greater disease burden
than previously appreciated. The construction of
dams and the development of important irrigation
schemes are often followed by epidemic outbreaks of
the disease. Despite the availability of the highly ef-
ﬁcient drug, praziquantel (PZQ), there is consider-
able spreading of schistosomiasis into new endemic
areas (Ross et al. 2002). After many years of experi-
ence it is generally agreed that mass PZQ chemo-
therapy, although the mainstay of current control
programmes, does have signiﬁcant limitations. In
particular, mass treatment does not prevent re-
infection. Furthermore, despite the fact there is not
yet clear-cut evidence for the existence of PZQ-
resistant schistosome strains, decreased suscepti-
bility to the drug has been reported in several
countries. Although schistosomiasis is eﬀectively
treated with PZQ, rapid reinfection with rebound
morbidity precludes eﬀective control based on
chemotherapy alone and justiﬁes current eﬀorts to
develop vaccines for these parasites.
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Unlike the African schistosomes (S. mansoni,
S. haematobium), schistosomiasis japonica is a
zoonosis and a major disease risk for more than 40
million people living in the tropical and sub-tropical
zones of China (Chen and Feng, 1999) and several
millions more in the Philippines (Blas et al. 2004).
Despite extensive and concerted control eﬀorts, it is
estimated that over one million Chinese and several
hundred thousand livestock, including over 200 000
bovines, are currently infected (Ross et al. 2001) with
the major endemic foci being the marsh and lake
regions of Southern China. Construction of the
massiveThreeGorgesDam across the Yangtze River
in Southern China is expected to increase schisto-
somiasis japonica transmission signiﬁcantly and in-
troduce the infection into areas currently unaﬀected
(Ross et al. 2001). Vaccines (for use in livestock
animals, particularly bovines and humans) in com-
bination with other control strategies, including the
use of new drugs, are needed to make elimination
of the disease possible (Todd and Colley, 2002).
The approach that several groups (Shi et al. 2001;
He et al. 2003; Zhang et al. 2006; Zhu et al. 2006)
are taking incorporates the development of a trans-
mission blocking veterinary vaccine. The vaccine
would be used in reservoir hosts of S. japonicum that
potentially will reduce transmission to humans at
least in China. Bovines (cattle and water buﬀalo) are
the major reservoirs for S. japonicum infection
in China with estimates that 90% of egg contami-
nation comes from this source (Chen and Lin, 2004).
Schistosomiasis japonica was once highly prevalent
in other domestic animals such as pigs but, in recent
years, these animals have been of less importance
because they are usually restricted to pens, with
limited access to the marshland areas. Sheep and
goats are also infected but to a far lesser extent and, as
wild animals become rarer and rarer, their involve-
ment in transmission can probably be ignored (Chen
and Lin, 2004).
The results of control technology advances, in-
cluding the success of recent World Bank inputs,
were used by Willams et al. (2002) to mathemat-
ically model prospects for the future control of
schistosomiasis in China. Another mathematical
model of the dynamics and control of S. japonicum
transmission on Bohoiol island, the Philippines
was developed by Ishikawa et al. (2006). Further-
more, a bovine drug intervention trial (Guo et al.
2006) was recently concluded in schistosome-
endemic communities in Jiangxi Province, China,
which indicated that buﬀalo are responsible for
75–80% of schistosomiasis transmission in the
marshland areas.
A recently published special issue of Acta Tropica
entitled ‘‘Control of Schistosomiasis in China’’
(Volume 96, issue 203, 2005) provides a major over-
view of control strategies, including vaccine devel-
opment, and provides a unique insight into various
facets of the disease that are entirely complementary
with this review.
S. japonicum vaccine development – basic
considerations
Convincing arguments support the likelihood that
eﬀective vaccines against schistosome infection can
be developed. Recent progress has provided the
basic framework for the development of an eﬀective
vaccine against S. japonicum and S. mansoni and
comprehensive reviews of the area are available
(Pearce, 2003; Hagan and Sharaf, 2003; McManus
and Bartley, 2004; Lebens et al. 2004; Capron et al.
2005; Da’dara and Harn, 2005; McManus, 2005;
Wu, Lu and Yu, 2005). Schistosomulum life cycle
stage antigens are likely to be major vaccine candi-
date targets of protective immune responses.
Zoonotic transmission adds to the complexity of
S. japonicum control programmes, but provides a
unique opportunity to develop a transmission
blocking veterinary vaccine to help prevent human
infection and disease. Vaccination with radiation-
attenuated cercariae induces signiﬁcant levels of
resistance to S. japonicum challenge in mice, rats,
rabbits, sheep and bovines; in the case of water
buﬀalo, greater than 95% protection has been
achieved (Shi et al. 1990) by immunization with
an ultaviolet-irradiated cercarial vaccine. The initial
protection in mice is conferred by Th1 cellular
immunity with lymphoid proliferation in regional
and mediastinal lymph nodes. Appropriately timed
passive transfer of sera from vaccinated mice can
also confer protection. This protection is antibody
mediated, with predominantly IgG (less so IgM)
antibodies acting on the lung schistosomula stage.
IgE depletion did not inﬂuence protection in these
studies. Later, extensive studies both in animal
models and in humans suggest that both Th1 and
Th2 responses may contribute to protection (Pearce
and MacDonald, 2002; Capron et al. 2005; Leenstra
et al. 2006). Unfortunately, studies of protective
immunity, in bovine schistosome infections are
few (De Bont and Vercruysse, 1998), and, conse-
quently, our knowledge of the immunology of
S. japonicum infections in bovines is extremely lim-
ited. This is particularly the case for water buﬀalo
where immunological reagents for studying immune
responses are scarce. Studies on the immunology of
buﬀaloes represent an important area for future
research as such information may prove useful in
candidate S. japonicum vaccine antigen selection and
in deﬁning the optimum route of immunization.
VACCINE CANDIDATES AND PROTECTIVE
POTENCY
Considerable eﬀorts have been aimed at the identi-
ﬁcation of relevant S. japonicum antigens that may be
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involved in inducing protective immune responses,
with a view to developing them further as viable
vaccines. Vaccination can be either targeted towards
the prevention of schistosome infection or to the re-
duction of parasite fecundity. A reduction in worm
numbers is the gold standard for anti-schistosome
vaccine development but, as schistosome eggs are
responsible for both pathology and transmission,
a vaccine targeted on parasite fecundity and egg
viability appears is also relevant.
Some of the leading S. japonicum vaccine candi-
dates (as recombinant protein and/or DNA vaccines)
are discussed below and their protective eﬃcacy in
diﬀerent animal models summarised. The majority
are membrane proteins, muscle components or en-
zymes and further details of the characteristics and
eﬃcacy of these and other molecules can be found in
Wu et al. (2005) and McManus (2005).
Glutathione S-transferase (Sj26GST)
Gluathione S-transferases (GSTs) are a group of
enzymes that catalyse the detoxiﬁcation of lipophilic
molecules by thio-conjugation. In light of their
physiological importance, a number of research
groups have investigated the potential of theGSTs as
vaccine targets. Some encouraging data are available
for the protective eﬃcacy of the Sj28GST against
S. japonicum in China (McManus, 2005) but most
work has concentrated on the 26 kDa isoform.
Recombinant (r) Sj26GST induces a pronounced
anti-fecundity eﬀect, as well as a moderate but sig-
niﬁcant level of protection in terms of reduced worm
burden in mice, sheep, cattle and pigs following
challenge infection with S. japonicum (Wu et al.
2005). Similar levels of vaccine eﬃcacy were ob-
tained in water buﬀaloes vaccinated with puriﬁed
reSj26GST (Wu et al. 2005). Anti-Sj26GST anti-
bodies were produced in the immunised buﬀaloes
and, following challenge with S. japonicum cercariae,
the typical anti-fecundity eﬀect wasmanifest, charac-
terized by a signiﬁcant decrease in faecal egg output
and eggs deposited in host tissues with those in the
liver and intestine being reduced by about 50%. In
addition to the anti-fecundity eﬀect, reSjc26GST
reduced by nearly 40% the egg-hatching capacity of
S. japonicum eggs into viable miracidia. Recent ﬁeld
trials have demonstrated that the protective eﬀect of
the reSjc26GST vaccine against S. japonicum can
be maintained in cattle and buﬀaloes for at least 12
months (Wu et al. 2005; McManus, 2005).
Paramyosin (Sj97)
Paramyosin (pmy) is a 97 kDa myoﬁbrillar protein
with a coiled-coil structure and is found exclusively
in invertebrates. Expressed on adults and the tegu-
mental surface of lung-stage schistosomula, it
appears to be multifunctional. It may act as a re-
ceptor for Fc, and an exogenous form inhibits acti-
vation of the terminal pathway of complement
implying an important immunomodulatory role in
schistosomiasis (Gobert and McManus, 2005).
Native and recombinant pmy (Sj97) confer protec-
tion against S. japonicum in mice, buﬀalo and other
mammalian hosts (Wu et al. 2005). Furthermore,
recent studies of human T helper2 (Th2) cytokine
responses to Sj97 add further support to this mol-
ecule as a leading vaccine candidate against S. japo-
nicum (Leenstra et al. 2006). Unfortunately, a major
challenge with Sj97 is its poor expression in soluble
form, probably due to its coiled coil structure and its
large size. To improve its expression and to identify
protective epitopic regions on paramyosin, the pub-
lished Chinese Sj97 cDNA sequence was recently
redesigned usingPichia codon usage and divided into
four overlapping fragments (fragments 1, 2, 3, 4) of
747, 651, 669 and 678 bp, respectively (Zhang et al.
2006). These gene fragments were synthesized and
expressed in Pichia pastoris (fragments 2 and 3) or
E. coli (fragments 1 and 4). The recombinant pro-
teins were produced at high level and puriﬁed using
a two-step process involving Ni-NTA aﬃnity
chromatography and gel ﬁltration. BALB/c mice
were immunized subcutaneously three times at 2
week intervals with the puriﬁed proteins formulated
in adjuvant Quil A. The protein fragments were
highly immunogenic, inducinghigh, though variable,
ELISA antibody titres, and each was shown to re-
semble native paramyosin in terms of its recognition
by the anti-fragment antibodies in Western blotting.
The immunized mice were subjected to cercarial
challenge 2 weeks after the ﬁnal injection and
promising protective eﬃcacy in terms of signiﬁcant
reductions in worm burdens, worm-pair numbers
and liver eggs in the vaccinated mice resulted.
There was no apparent correlation between the
antibody titres generated and protective eﬃcacy, as
all fragments produced eﬀective but similar levels
of protection. These fragments now need to be
tested further for protective potency both separately
and in combination in larger animals including buf-
faloes.
Very low density lipoprotein-binding protein
(SVLBP)
An expressed sequence tag (EST) of S. japonicum
encoding aS. japonicum very low-density lipoprotein
binding protein (SVLBP; molecular size, 20 kDa)
was reported to be membrane-associated, and lo-
cated in the tegument and sub-tegument of adult
male schistosomes (Fan et al. 2003). Given that the
SVLBPmay play an essential role in lipid acquisition
by the parasite, and/or in signal transduction path-
ways, its further investigation for development as a
novel anti-schistosomal intervention was warranted.
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Accordingly, Gan et al. (2005) used aﬃnity puriﬁed
recombinant (r) SVLBP to vaccinate mice. The
worm numbers and egg deposition recovered from
the livers and veins of the immunized mice were
33.5% and 47.6% less than those from control mice,
respectively. There was also a marked increase in
the antibody response in vaccinated mice: the titre
of IgG1 and IgG2a, IgG2b in the vaccinated group
was signiﬁcantly higher than that in the controls.
In a comparison of the reactivity of sera from
healthy individuals and patients with rSVLBP, rec-
ognition patterns against this parasite tegumental
antigen varied among diﬀerent groups of the
individuals. Notably, the average titres of anti-
rSVLBP antibody in sera from faecal egg-negative
individuals was signiﬁcantly higher than that in
sera from the faecal egg-positives, which may
reﬂect SVLBP-speciﬁc protection. These results
suggest that the parasite tegumental protein SVLBP
is a promising candidate for further investigation as
a vaccine antigen for use against Asian schisto-
somiasis but further testing is now required to assess
its true value.
Serine protease inhibitor (Sj serpin)
Serine proteinase inhibitors (serpins) represent an
important superfamily of endogenous inhibitors that
regulate proteolytic events active in a variety of
physiological functions. Yan et al. (2005) used
immunological screening of a S. japonicum adult
worm cDNA expression library with sera ofMicrotus
fortis, a naturally resistant vertebrate host, and
identiﬁed one clone that encoded for a sequence
homologous to those of the serpin superfamily.
The full-length sequence encoding S. japonicum
serpin (Sj serpin) was ampliﬁed from adult worm
cDNA by using 5k-RACE-PCR and subsequently
cloned into the prokaryotic expression vector
pET28c. The full-length Sj serpin fusion-protein
with his-tag was expressed in E. coli, puriﬁed by
aﬃnity chromatography and used to immunize
New Zealand white rabbits. Sj serpin is located on
the tegument in S. japonicum adult worms. C57BL/6
mice immunized with Sj serpin induced the
production of high levels of speciﬁc IgE and
IgG1 subclass antibodies as well as a marked IL-4
response. Lymphocyte surface marker analysis
revealed proliferation of CD19-expressing B cells,
indicating a predominant Th2-type response to
Sj serpin. Immunized mice developed moderate
protection against infection of S. japonicum as
demonstrated by a 36 and 39% reduction in the re-
covery of adult worms and eggs, respectively.
Further vaccine-challenge experiments with Sj
serpin, modifying the delivery of the vaccine
and testing diﬀerent adjuvant formulations, will
enable a better assessment of its potential as a vaccine
candidate.
Triose-phosphate isomerase (SjTPI)
The glycolytic pathway enzyme triose-phosphate
isomerase (TPI) is found in each cell of each stage of
the schistosome life cycle and the S. mansoni enzyme
(SmTPI) has long been targeted as a schistosomiasis
vaccine candidate. As the two schistosome TPI se-
quences are very similar (84% identity), it was logical
to assess the protective eﬃcacy of SjTPI both as a
recombinant protein and plasmid DNA vaccine.
Encouraging results were obtained in early exper-
iments on mice but to examine the transmission
blocking potential in large animals, Zhu et al. (2004)
determined the vaccine eﬃcacy of Chinese SjTPI
(SjCTPI) plasmid DNA in naive pigs. Pigs were
vaccinated with the TPI DNA-plasmid alone, or
in conjunction with IL-12 as pcDNA3.1-P35,
pcDNA3.1-P40 plasmids via intramuscular injec-
tion. Control pigs were immunized with equivalent
amounts of pcDNA3.1. Pigs were immunized 3
times at 21-day intervals and challenged 30 days after
the ﬁnal boost. Forty-ﬁve days post-challenge, pigs
were sacriﬁced and perfused to compare adult worm
burdens, female worm burdens, liver egg burdens
and granuloma size. They found that pigs vaccinated
with SjCTPI DNA alone had adult worm burdens
reduced by 48.3% and that a further decrease in adult
worm burdens was not seen in the group vaccinated
with SjCTPI DNA in conjunction with IL-12
(46.2% reduction). The SjCTPIDNAvaccines had a
more pronounced eﬀect on reducing female worm
burdens i.e. 53.6% SjCTPI alone and 59.6% for
SjCTPI+IL-12. Vaccination with SjCTPI-DNA
reduced liver eggs by 49.4% and this response was
signiﬁcantly enhanced by the addition of IL-12
(65.8% reduction in liver eggs). In addition to the
dramatic protective eﬀects seen in vaccinated pigs,
they also noted that granuloma size was reduced by
42% in both groups. Though encouraging, further
extensive experimental and ﬁeld-based trials on
bovines, particularly buﬀaloes, are now required in
China to determine whether vaccination with the
SjCTPI DNA vaccine will likely reduce trans-
mission by reducing adult worm burdens and worm
egg output, with simultaneous reduction of hepatic
egg-associated pathology.
23 kDa integral membrane protein (Sj23)
As with TPI, the schistosome integral membrane
protein (Sm/Sj23) was identiﬁed as a major vaccine
candidate some years ago, ﬁrst against schisto-
somiasis mansoni and then schistosomiasis japonica.
The S. japonicum Chinese strain form (SjC23) was
initially shown to induce protection in mice as a
synthetic peptide vaccine and then as a plasmid
DNA vaccine to induce protection in mice, sheep,
pigs and water buﬀalo. Overall, the results from the
extensive plasmid DNA vaccine studies indicated
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that vaccination with SjC23DNA induced not only a
signiﬁcant reduction in worm and egg burdens, but
also signiﬁcantly reduced the size of egg granulomas;
thus, like SjCTPI, SjC23 produced an anti-
pathology eﬀect as well. The protective eﬀect of
the SjC23 plasmid DNA vaccine was enhanced with
IL-12 in pigs (Zhu et al. 2004) and mice (Gan et al.
2005), and by CpG immunostimulatory sequence in
mice (Zhao et al. 2005). As with the other candidate
vaccines, extensive large animal ﬁeld trials are now
required to determine the precise protective potency
of SjC23 with or without IL-12 or CpG.
Fatty acid-binding protein (SjFABP)
Like other parasitic helminths, schistosomes are
unable to synthesise long chain fatty acids or sterols
and hence are completely dependent on the host for
these components. Fatty acid binding proteins
(FABPs) are critical for schistosomes to take up fatty
acids from host blood as essential nutrients, and are
thus prime targets for both vaccination and drug
development. The 14 kDa FABP of Chinese strain
S. japonicum (SjFABPc) has at least eight diﬀerent
variants encoded by a single-copy polymorphic gene,
and it is particularly important to S. japonicum for
uptake, transport and compartmentalisatioin of host-
derived fatty acids, playing a vital role in the physi-
ology and survival of the parasite. Several Chinese
groups have obtained encouraging protection with
(SjFABPc) in mice both as a recombinant protein
and plasmid DNA vaccine. Especially noteworthy
are the studies by Liu et al. (2004) who expressed
SjFABPc in Escherichia coli and in Baculovirus/
silkworm systems. The recombinant protein from
E. coli was a 41 kDa GST fusion protein (rSj14/
GST), which could be puriﬁed by glutathione
agarose aﬃnity chromatography, with a yield of
25 mg/L E. coli culture. The recombinant protein
from the Baculovirus/silkworm system was an
18 kDa fusion protein (rSj14/His), which could be
puriﬁed by Ni-NTA resin chromatography column
with a yield of 3.5 mg per silkworm larva. Both
rSj14/GST and rSj14/His were recognized by
S. japonicum-infected mouse sera and anti-rSj14/
GST mouse sera in Western blotting. The puriﬁed
recombinant protein was immunogenic in mice, rats
and sheep, and 34.3%, 31.9% and 59.2% worm re-
ductions, respectively, were obtained in vaccinated
Kunming mice, Wistar rats and sheep vaccinated
with Sj14/GST, compared to non-vaccinated control
groups. Worm reductions of 48.8% and 49.0% were
recorded in BALB/cmice immunized with Sj14/His,
compared to non-vaccinated and BCG-vaccinated
groups, respectively. Taken together, these results
emphasise the promise of SjFABPc as a candidate
vaccine for schistosomiasis japonica, particularly as
in the rat and sheep vaccination experiments, no
adjuvant was used.
Another group (Zhu et al. 2005) studied the pro-
tective eﬃcacy of SjFABPc as a DNA vaccine
enhanced by IL-12 in mice challenged with
S. japonicum. They showed that IL-12 drives the
immune response toward a Th1 direction, and en-
hanced the protective eﬀect of the vaccine.
VACCINES AGAINST FASCIOLA HEPATICA
AND F . GIGANTICA
While certainly not responsible for as great a toll on
human mortality and morbidity as schistosomiasis,
fasciolosis is more important in terms of economic
loss to the global agricultural community. This loss
is estimated at >$2000 million annually, as >600
million animals are infected (Hillyer and Apt, 1997;
Spithill et al. 1999b). Like schistosomes, liver ﬂukes
are digenetic trematodes and therefore display
similar life cycles. However, infection is acquired
following ingestion of the infective larvae that lie
dormant within cysts rather than by penetration of
the skin by free-swimming larvae. Depending on the
climate, these cysts can remain viable in the en-
vironment for up to one year. Following excystment
in the intestine of the host the parasite burrows
through the intestinal wall, migrates through the
liver parenchyma for approximately two months
before moving into and taking up residence in the
bile ducts. These early migratory stages cause ex-
tensive perforations and haemorrhaging of the liver
which can result in death in cases of heavy infection,
particularly in susceptible species such as sheep.
Chronic disease can persist for several years in cattle
and many years (as long as 20) in sheep. Within the
bile ducts mature hermaphroditic ﬂukes liberate up
to 20–50 000 eggs per day per parasite that are carried
with the bile juices into the intestine and are passed
onto the pastures in the faeces (Whitﬁeld, 1979;
Andrews, 1999).
Fasciolosis is caused by two species of liver ﬂuke,
Fasciola hepatica and Fasciola gigantica. The main
intermediate host for F. hepatica in Europe is Galba
truncatula but other varieties such asL. tomentosa are
more important in Australia and New Zealand and
Pseudosuccinia columella in South America. The in-
termediate hosts of F. gigantica, the Eurasian Radix
auricularia and African R. natalensis, are resistant to
infection with F. hepatica and, conversely, F. gigan-
tica does not appear to develop in Galba truncatula
(Graczyk and Fried, 1999; Mas-Coma, Barques and
Valero, 2005).
Although believed to be of European origin, due to
the capacity of F. hepatica to infect many diﬀerent
species and to the ability of the intermediate snail
host to adapt to a wide range of ecological niches, the
parasite has now a cosmopolitan distribution (Mas-
Coma et al. 2005). Fasciolosis is still generally associ-
ated with more temperate climates and besides being
highly prevalent throughout Europe, it is now found
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in the southern states of the US, Mexico, North
Africa, New Zealand and small regions within
Australia. The parasite infects primarily cattle and
sheep, although other domesticated animals such as
goats, horses and pigs can be infected. Other hosts
include llamas in South America, camels in Africa
and marsupials in Australia which may play im-
portant roles as reservoir hosts in these regions. The
introduction of F. hepatica to South America by
Europeans since the 18th Century has seen it become
a major problem in Brazil, Argentina, Uruguay and
in several Andean countries such as Bolivia, Peru and
Equador (Mas-Coma et al. 2005).
In Europe and Australia where chemical products
are used as the almost sole means of disease control
parasites resistant to the major anti-ﬂukicide, tricla-
bendazole (FasinexR, Novartis Animal Health), have
emerged. Problems of drug-resistance will increase
as this drug has recently come oﬀ patent protection
and various generics are currently being sold. Some
less eﬀective ﬂukicide products are still available (e.g.
clorsulon) and new mixtures of old products have
being recently marketed, but the likelihood of novel
chemical products being developed is small given the
heightened regulations and costs associated with
drug research and development. Thus, the future
control of fasciolosis hepatica will depend on the
development of an eﬀective vaccine.
Disease caused by F. gigantica, a larger but more
slender ﬂuke, has a relatively restricted distribution
due to the reduced ability of the intermediate hosts to
invade new niches and is generally found in tropical
regions, being recorded in Africa, South and East
Asia, the Middle East and eastern Europe. This
parasite has been largely neglected even though, as
highlighted by Spithill et al. (1999b), it is regarded
as one of the most important single helminth infec-
tions of ruminants in Asia and Africa. Since the
disease is more prevalent in less well-oﬀ communi-
ties it impacts signiﬁcantly on local or family econ-
omies. For example, in some regions of Indonesia
the prevalence in some areas can reach 90% and
annual losses to the country as a whole are in excess
of US$100 million. Similar to infection with
F. hepatica, this disease results in lower weight gains,
reduced milk production, poorer quality of meat,
reduced fertility and reduce work capacity. The
parasite infects mainly cattle and sheep but in Asia
infection of water buﬀalo, the main source of draught
power, is of greater signiﬁcance.
The distribution of F. hepatica and F. gigantica
overlap in various regions in the Far East where
fasciolosis is important, including Japan, Korea,
Taiwan and the Phillipines. Signiﬁcantly, this has
given rise to mixed parasite forms, seemingly by
natural hybridisation (Agatsuma et al. 2000), with
morphological and genetic features that range in
the two extremes; for example, forms often referred
to as Fasciola spp. in Japan have mtDNA NDI









Infection with Fasciola sp. is
by ingestion of dormant larvae.
Larvae rupture and penetrate intestinal
wall. Hermaphroditic worms reside in liver.
Active infection with Schistosoma japonicum
when larvae penetrate skin. Mature male and
female worms reside in mesenteric veins
Definitive host
Water buffalo are
definitive hosts for S.
japonicum,
F. hepatica and F.
gigantica.
F. hepatica and F.
gigantica can infect
sheep and cattle
Fig. 1. The life cycles of the zoonotic trematodes S. japonicum, Fasciola hepatica and Fasciola gigantica have certain
similarities ; the ﬁgure above highlights some important diﬀerences. The parasites use similar molecules (proteases,
anti-oxidants etc.) in key aspects in host-parasite interaction. It is not surprising, therefore, that similar strategies for
vaccine discovery for the prevention and transmission of infection have been employed by researchers and,
consequently, that many of the lead vaccine candidates are homologs in these parasites. Figure drawn by JPD.
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and ITS-2 sequences of nuclear rDNA identical
with either F. gigantica or F. hepatica (Itagaki and
Tsutsimi, 1998).
HUMAN FASCIOLOSIS – A RE-EMERGING
PROBLEM
Since infection is acquired through ingesting infec-
tive larvae fasciolosis in humans is considered a food-
borne zoonotic disease. However, the importance of
human fasciolosis has only been recognised in the last
decade. Prior to 1992 total reported cases of human
fasciolosis was estimated to be <3000 but more re-
cent studies provide ﬁgures of 2.4 million (Rim et al.
1994; Curtale, Hassanein and Savioli, 2005) and
17 million (Hopkins, 1992). While the actual situ-
ation remains unclear it is certain that, due to the
increased number of surveys carried out with
better diagnostic assays, human fasciolosis is highly
prevalent in certain regions of the world. Human
infection is always associated with local endemic
animal fasciolosis, although the distribution of
human infection and level of prevalance may not
always correlate with that observed in animals
(Mas-Coma, 2004; Mas-Coma et al. 1999a, 2005).
Moreover, parasites in humans produce viable eggs
and thus play a part in the overal transmission of
diseases (Mas-Coma et al. 2005).
After initial reports of human infection in Bolivia
(Hillyer et al. 1992; Bjorland et al. 1995) several
major epidemiological studies revealed that human
infection is highly prevalent (100% in some areas) in
the high altitude Andean rural regions stretching
from northern Bolivia, through Peru, to Equador
(Mas-Coma et al. 1999a, b ; O’Neill et al. 1998,
1999a). Infection is found in mainly indigenous
peoples, subsistance farmers who regularly share the
same water sources with their animals. Infection is
more prevalant in children but is present in all ages
of both sexes (Mas-Coma et al. 2005). Since the
parasites can live in humans for up to 13 years and
produce large numbers of eggs (up to 5000 eggs per
gram faeces in some Bolivian children) that are in-
fective to other hosts, humans may play a signiﬁcant
part in disease transmission (Mas-Coma et al. 1999b),
as observed for schistosomiasis japonicum in China
(Williams et al. 2002; Guo et al. 2006; Ishikawa et al.
2006).
Human infection is also prevalent, with regular
outbreaks involving up to 10 000 infections, in the
Guilan and Mazandaran provinces of northern Iran
that border the southern end of the Caspian Sea
(Rokni et al. 2002; Moghaddam et al. 2004). Esteban
et al. (2003) recently reported hyperendemic human
disease in the Nile Delta region between Cairo and
Alexandria in Egypt (ranging in prevalence from 5
to 19%) and estimate that as many as 830000 in-
dividuals are infected here. Schistosomiasis mansoni
is also endemic in this region (more than double that
of fasciolosis) and the relationship of its prevalence
and intensity with sex and age showed patterns
similar to that found with fasciolosis. The inter-
mediate hosts of both parasites have penetrated the
irrigation streams and, therefore, control pro-
grammes here will need to consider both diseases
(Esteban et al. 2003; Curtale et al. 2005). Immuno-
supression induced by liver ﬂukes (and schistosomes)
may contribute to the susceptibility of humans to
other infections as multiparasitism, particularly
with other food-borne pathogens such as Giardia
intestinalis, has been observed in surveys in Egypt
and South America (Brady et al. 1999; Mas-Coma
et al. 2005).
Human infection in Europe occurs more sporadi-
cally, but countries such as France, Spain and
Portugal are experiencing signiﬁcant and consistent
cases of infections, approximately 50 to 100 per year
(Mas-Coma et al. 2005). Infection is usually due to
the ingestion of various freshwater aquatic plants,
such as watercress, on which the metaceracariae have
settled. Farm management practices and the cultur-
ing of edible aquatic plants in geenhouses has limited
the extent of human infection in more industrialised
regions but in South America, Egypt and Iran wild
aquatic plants or plants grown in ﬁelds where in-
fected animals can freely roam form a regular part of
the daily diet. Since these are often sold at local or
distant food markets outbreaks of human infection,
such as that experienced in the town of Rasht in
northern Iran (Rokni et al. 2002), can occur far from
the site of vegetable contamination with meta-
cercariae. Metacercariae can also be found ﬂoating in
water and, therefore, infection can be acquired
through drinking water, even from piped sources
(Mas-Coma, 2004).
Most human cases are with F. hepatica, with a few
reports of F. gigantica infection in the tropics (see
Mas-Coma et al. 1999a). Several recent reports are
indicating a rising problem with fasciolosis in
Vietnam, although the complete picture remains
unclear (Hien et al. 2001). It is likely, however, that a
detailed survey of rural liver ﬂuke-endemic regions
in the Asia would reveal greater human infection
since the lack of farm management, the sharing of
water sources by animals and humans and the like-
lihood of contamination of edible aquatic plants and
rice with infective ﬂuke metacercariae is similar to
that observed in other regions where fasciolosis is an
important zoonosis.
Theoretically, human fasciolosis could be con-
trolled by introducing strict farm management
practices, prevention of food contamination and a
change of eating habits but, for obvious reasons, this
is not practical in areas where disease in prevalent.
However, two recent advances will be important
for the future detection and control of human disease
(in both edemic and non-endemic regions) ; ﬁrstly,
a cheap sensitive and speciﬁc immunodiagnotic
Vaccines against Schistosoma japonicum and Fasciola S49
ELISA test that detects antibodies in human serum
or plasma (or in blood taken onto ﬁlter paper) has
been developed (O’Neill et al. 1998; Strauss et al.
1999; Rokni et al. 2002) and second, the ﬂukicide
triclabendazole has been formulated into tablets for
human use (EgatenR, Novartis) and is highly eﬀec-
tive (80%) against both F. hepatica and F. gigantica
infection when given in dose of 10 mg per kilogram
and almost 100% eﬀective when given in two doses
(Curtale et al. 2003, 2005; Savioli, Chitsulo and
Montresor, 1999).
PROGRESS TOWARDS VACCINE DEVELOPMENT
The development of vaccines for controlling animal
and human fasciolosis is of critical importance. The
lack of protection against the spread of drug-resistant
F. hepatica in the major agricultural economies will
be the main force that will drive this development
and its commercialisation. Moreover, there appears
to be a increase in animal fasciolosis in Europe,
possibly due to weather changes (Fairweather and
Boray, 1999). Support from the EU Commission
under the Sixth Framework Programme (FP6) for a
newmajor global project (DELIVER) that will focus
on the control of fasciolosis and the understanding
of drug resistance is an acknowledgement of the
growing importance of this disease and should give
research in this area a major boost (Jose Perez,
University of Cordoba, Cadiz, Spain, personal
communication). Additionally, there has been a
noticeable renewed interest in fasciolosis amongst
the major animal health multinationals and now that
the costs and legislation associated with new drug
development have become more onerous the notion
of exploiting recombinant vaccines is becoming
a realisitic option from a commercial point of view.
Substantial strides have taken place in our under-
standing of the molecular biology of F. hepatica and
F. gigantica and there is now a rich source of more
than 4000 expressed sequences tags (EST) (www.
sanger.ac.uk/Projects/S_mansoni/) from which vac-
cine candidates can be ﬁshed using random or
rational criteria. The diﬀculty in employing high-
throughput techniques for identifying putative vac-
cine candidates, such as signal sequence trap that
identiﬁes secreted or membrane-bound antigens (see
Dalton et al. 2003a), is the lack of consensus on a
biological property or molecular characteristic that is
predictive of vaccine potential. Additionally, there
is no suitable in vitro assay or even laboratory model
that lends itself to testing large numbers of vaccines.
Accordingly, most of our present vaccine candidates
for fasciolosis have been known for some time and
were discovered using basic biochemical and/or
immunological methods for investigating parasite
excretory-secretory (ES) products or by systemati-
cally analysing chromatographically separated frac-
tions of parasite extracts that provide protection in
experimental models. These candidates have been
reveiwed in a excellent recent paper byHillyer (2005)
so in the present report we will summarise these in
terms of their phase of development.
CANDIDATES PROGRESSED TO RUMINANT
VACCINE TRIALS
Fatty acid-binding proteins
The potential of using immunologically cross-
reacting antigens to target both F. hepatica and
S. mansoni was pursued by Hillyer and colleagues in
a series of vaccine trials in mice since the early 1970s
(see Hillyer, 2005) and led to the discovery of the
fatty acid binding proteins (FABP). FABPs are ma-
jor components of whole ﬂuke extracts and are also
found in ES products. They represent a hetero-
geneous family of proteins as revealed by 2-D elec-
trophoresis (Jeﬀeries et al. 2001) and several diﬀerent
genes are deposited in the public database. FABP
function in the transport of hydrophobic ligands and
since trematodes cannot synthesis long chain fatty
acids de novo the parasite may use FABPs to
sequester these from host serum (Spithill, Smooker
and Copeman, 1999a).
One of the native FABP forms of 12 kDa (nFh12)
was selected from a gel permeation fraction of adult
liver ﬂukes for their immunoprophylactic potential
against schistosomes and liver ﬂukes following ex-
tensive vaccine studies in mice (see Hillyer, 2005).
The recombinant counterpart (rFh15) of this mol-
ecule has given impressive vaccine results in rabbits
against a heterologous challenge with F. hepatica ;
levels of protection of 40%, 43% and 76% were ob-
served in various experiments which varied the time
between vaccination and challenge. Protection was
positively correlated with longer periods between
vaccination and challenge whichmay be important in
suﬃcient high titres of speciﬁc high-aﬃnity anti-
body. The vaccine also had similar large reductive
eﬀects on ﬂuke size, egg production (anti-fecundity)
and pathology (Muro et al. 1997; Casanueva et al.
2001). In subsequent vaccination trials in sheep
(Castillian breeds in Spain) using nFh12 and rFh15
similar high levels of protection were not observed
but the results highlighted the importance of
the adjuvant in which the vaccine was formulated
(Ramajo et al. 2001; Martinez-Fernandez et al.
2004). For example, when formulated in Freund’s
adjuvant no reduction in ﬂuke burden or develop-
ment was seen although eﬀects on faecal eggs counts
were signiﬁcant. However, when the native molecule
was formulated in saponin fromQuillaja saponaria or
a hydroalcoholic extracts of Polypodium leucotomos
and emulsiﬁed in a non-mineral oil (Montanide),
ﬂuke recoveries in vaccinated sheep where signiﬁ-
cantly lower (23.5%), ﬂuke development was re-
tarded (by approximately 35%) and egg counts in
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bile and faeces were reduced by 58.1% and 40.3%,
respectively.
A 12 kDa protein from F. hepatica which showed
sequence homology to FABP but was diﬀerent to
rFh15 was described by Bozas and Spithill (1996).
The native molecule, termed FABP3, was isolated
by reverse phase HPLC and tested in cattle, but
no protection was observed. The negative result
could be contributed to the destruction of protective
epitopes by denaturing conditions used during
puriﬁcation, and it is possible that the adjuvant used
(DEAE) was not appropriate to induce the required
immunological responses (Spithill et al. 1999b).
Recent studies in mice by Lopez-Aban et al.
(1999, 2000) have shown the potential of nFh12 and
rFh15 to protect against S. bovis in mice (as high as
96%), albeit this protection was strain dependent.
Tendler and colleagues (Tendler et al. 1996)
characterized a 14.8 kDa S. mansoni FABP (Sm14)
which, in recombinant form, could induce protec-
tion in mice to both S. mansoni and F. hepatica
(Almeida et al. 2003). The schistosome molecule
is homologous to rFh15 and certain peptides
(EKNSESKLTQ and VTVGDVTA) that match
sequences in both molecules exhibit protective
property similar to that of recombinant Sm14 (Vilar
et al. 2003). Sm14 was also reported to protect sheep
from a challenge infection of F. hepatica and, while
the numbers of animals used in this single trial were
low, the eﬀects on ﬂuke burdens were very high
(59.2%) (Almeida et al. 2003).
Cysteine peptidases
The most abundant proteins secreted by adult liver
ﬂukes are cathepsin L cysteine peptidases (approxi-
mately 24.5 kDa). These belong to a large hetero-
genous family encoded by at least seven diﬀerent
genes (Tort et al. 1999; Dalton et al. 2003a). They
are synthesised and secreted by the epithelial cells
lining the parasite gut and function in the degra-
dation of the blood meal in the gut lumen (Collins
et al. 2004). Since the contents of the gut are emptied
approximately every three hours, these peptidases
are also delivered to the exterior in large quantities
where they perform additional functions such as
facilitating penetration of host tissue (intestinal wall,
liver parenchyma and bile duct) by the migrating
stages of the parasites and preventing host immune
attack by cleaving immunoglobulins and sup-
pressing the development of protective Th1 re-
sponses (Dalton and Mulcahy, 2001; Dalton et al.
2003b).
Two cathepsin L peptidases, cathepsin L1 and
cathepsin L2, have been the most extensively studied
vaccine candidates and trials have been carried out in
both sheep and cattle. These vaccines have given
consistent protection in cattle that ranges from
38.2%–68.5%. A cocktail of the two enzymes has
never been tested in cattle but when cathepsin L1 and
cathepsin L2 were combined with another antigen, a
ﬂuke haemoglobin, protection levels of 51.9% and
72.4% were obtained, respectively (Dalton et al.
1996, 2003b). In all of these trials a large reduction in
egg production and egg viability was observed in the
the peptidase-vaccinated animals; the anti-fecundity
eﬀect observed using cathepsin peptidases ranged
from 40% to 65%while the combination of these with
haemoglobin ranged from 80% to 98%.
Both cathepsin L1 and cathepsin L2 vaccines also
induced signiﬁcant protection in Uruguayan sheep
breeds (34% and 33% lower ﬂuke burdens, respect-
ively), and elicited strong anti-fecundity eﬀects (71
and 81%, respectively). A combination of the two
peptidases showed that a cocktail can enhance pro-
tection to 60% (anti-fecundity eﬀects were not
measured) (Piacenza et al. 1999). In contrast, vacci-
nation of AustralianMerino sheep with a preparation
of adult ﬂuke cysteine peptidases (possibly included
both cathepsin L1 and cathepsin L2) did not elicit a
protective response, although a large, 69.4%, re-
duction in egg output was observed (Spithill et al.
1999a).
The above results have been obtained using native
cathepsin L peptidase. Recently, Collins et al. (2004)
described the production of recombinant cathepsin
Ls in the methylotrophic yeast, Pichia pastoris, that
exhibit identical enzymatic and molecular charac-
teristics to the native peptidases. Thesemolecules are
currently under investigation in vaccination trials in
sheep and recently data using cathepsin L1 revealed
that this recombinant delivers protection levels
(35–45%) and anti-fecundity eﬀects (50%) that are
similar to those observed with the native molecules
(Dalton and Mulcahy, unpublished).
Leucine aminopeptidase
Leucine aminopeptidase is a 54 kDa metallo-
exopeptidase also secreted from the gut of liver
ﬂukes; its primary role is likely in food digestion
(Acosta, Goni and Carmona, 1998; Piacenza et al.
1999). When used together with cathepsin L1
and cathepsin L2 the levels of protection were in-
creased over the cathepsin L peptidases alone (see
above) and reached 79%. However, and perhaps
surprisingly, when the leucine aminopeptidase
was used as a vaccine alone it induced even higher
levels of protection (89.6%). Recently, Carmona
(2005) reported the production of a recombinant
protein expressed in Escherichia coli that induced a
statistically signiﬁcant 81% protection in rabbits
compared to adjuvant control.
Glutathione-S-transferase
Once the focus of intense vaccine research with
substantial commercial backing, the family of
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glutathione-S-transferase (GST) isoenzymes have
now been rather neglected. The original rationale
for choosing GST as vaccines against F. hepaticawas
their demonstrated eﬃcacy as vaccines against
S. haematobium. Additionally, the enzymes are se-
creted by liver ﬂukes and may play important
chemical neutralisation functions outside the para-
site as well as household intracellular detoxiﬁcation
roles (Spithill et al. 1999a, b). The inconsistent eﬃ-
cacy of these enzymes in both sheep and cattle trials
(even in direct repeat trials) has reduced optimism in
their use as vaccines. The native vaccine was tested in
a range of adjuvants with an overall average protec-
tion level of 29% (lowest 0% and highest 65%) in
sheep and 45% (lowest 19% and highest 69%) in
cattle (Dalton and Spithill, 1998; Spithill et al.
1999a). In most experiments, signiﬁcant reduction
in faecal eggs counts was observed (up to 65%), but
this eﬀect was also highly variable. The most eﬀec-
tive adjuvant in cattle, QuilA/Squalene Montanide,
was not eﬀective in sheep suggesting that each
species may require distinct vaccine formulations.
Vaccination of cattle with a S. bovis-derived GST
formulated in QuilA, Alum and Freund’s adjuvants
did not induce protection in cattle challenged with
metacercaraie of F. hepatica (De Bont et al. 2003).
CANDIDATES IN THE PIPELINE
A high molecular sized fraction which contained
ﬂuke haemoglobin enhanced the eﬃcacy of vaccines
containing cathepsin L1 or cathepsin L2 (see above)
and alone induced 43.8% protection in cattle (Dalton
et al. 1996). While haemoglobin was the major
component of this protective fraction (McGonigle
and Dalton, 1995) immunological screening of
cDNA libraries with the sera taken from protected
cattle prior to challenge led to the isolation of a
cDNA encoding a novel anti-oxidant termed thiol
speciﬁc anti-oxidant (now termed thioredoxin
peroxidase or peroxiredoxin) (McGonigle et al. 1997,
1998). Thioredoxin peroxidase (TPx) is secreted in
low amounts by the parasites and while not im-
munogenic in naturally infected animals it is highly
antigenic when used as a vaccine in Freund’s and
QuilA adjuvants. Recent data revealed that TPx is
involved in subverting the immune response of the
host by stimulating the recruitment and activation of
alternatively activated macrophages and thus oﬀers
the possiblity of developing a vaccine that intervenes
in the host-parasite immunological relationship
(Donnelly et al. 2005). Recombinant TPx with
functional anti-oxidant activity has been produced in
E. coli and is currently under trials as a vaccine
against fasciolosis in sheep (Dalton and Mulcahy,
unpublished).
A F. hepatica saposin-like or NK-lysin-like mol-
ecule thatmay be involved in lysing host erythrocytes
as they enter the parasite gut was isolated using sera
taken from rabbits four weeks after an experimental
infection (Reed et al. 2000; Espino and Hillyer,
2003). The recombinant form of the protein,
FhSAP-2, induced an impressive 81.2% protection
against worms in rabbits, a reduction in faecal
and gall bladder egg counts of 83.8% and 73%,
respectively, and concomitant alleviation of liver
pathology (Espino and Hillyer, 2003, 2004; Espino
et al. 2005).
A diﬀerent isotype of cathepsin L (termed
cathepsin L3; Harmsen et al. 2004) and cathepsin
L DNA vaccine contructs (Kofta et al. 2000;
Wedrychowicz et al. 2003) have been tested in
rats and elicited >90% and 61–75% protection, re-
spectively. Additional molecules that are being
characterized from F. hepaticawith vaccine potential
include cathepsin B cysteine proteases (Law et al.
2003; Meemon et al. 2004), thioredoxin reductase
(Maggioli et al. 2004) and enolase (Bernal et al. 2004).
CANDIDATE VACCINES FOR F . GIGANTICA
The development of vaccines for F. gigantica
depends, unfortunately, on the transfer of know-
how and technology from research performed on
F. hepatica. Studies on water buﬀalo, the main
source of income for many in Asia, have not been
reported mainly because animals are expensive and
trials are logistically diﬃcult to organise. One report
of a major vaccine trial in Braham-cross cattle using
native and recombinant FABP (rFh12), native GST,
native cathepsin L and native paramyosin was pub-
lished over eight years ago (Estuningsih et al. 1997).
In this trial, only native FABP appeared to induce
protection (31%) but this was with low signiﬁcant
values (P<0.026). A recent trial also did not observe
protection in sheep using native F. gigantica GST
formulated in saponin or alum hydroxide (Paykari,
Dalimi and Madani, 2002).
DISEASE TRANSMISSION – BLOCKING EFFECT
OF LIVER FLUKE VACCINES
A common feature of all the vaccines described above
is that concurrent with protection against parasites a
reduction of faecal eggs counts was also induced.
While it would seem obvious that a reduction of
parasite numbers would have a corresponding
knock-on eﬀect on the number of eggs produced and
released onto pastures, in many cases the eﬀects on
egg production is greater than the eﬀect on worm
burden; for example, vaccination with FABP and
cathepsin L proteases (see above). In some cases,
negative eﬀects on egg production have been ob-
served with little or no concurrent protection against
ﬂukes; for example, vaccination of sheep with native
cathepsin L proteases (Spithill et al. 1999a, b). The
results indicate that egg production is particularly
vulnerable to immunological responses generated by
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vaccination, which is not so surprising given that
most of the catabolic (feeding and breakdown of
nutrient) and biosynthetic (synthesis of egg and
eggshell components) energy of mature adult ﬂukes
is devoted to this process. Accordingly, it is easy to
understand that blocking of the uptake of host fatty
acids by anti-FABP antibodies or the digestion blood
components by anti-cathepsin L and anti-leucine
aminopeptidases would have a immediate negative
impact on the parasites’ ability to synthesis viable
eggs. Interestingly, immunological responses in-
duced by vaccination with GST appear to have no
consistent correlation with blocking of egg pro-
duction (Dalton and Spithill, 1998; Spithill et al.
1999b).
Presently, there is no means of knowing howmuch
impact a vaccine that reduces egg output would have
on the transmission of fasciolosis, particularly since
adult ﬂukes produce an estimate 20–50000 eggs per
hour and that infection of the intermediate snail
host with a single miracidium gives rise to approxi-
mately 600 infective metacercariae (Whitﬁeld, 1979).
Mathematical models, similar to those developed for
schistosomiasis japonicum (Williams et al. 2002;
Guo et al. 2006; Ishikawa et al. 2006), have not yet
been reported for fasciolosis but are needed to pre-
dict the impact of vaccines on disease transmission. If
we can draw an analogy with the study of Williams
et al. (2002) it is probable that a vaccine delivering a
75% anti-fecundity aﬀect would ensure mid-term
reduction of parasite transmission and long-term
elimination. Dalton et al. (1996) showed that vacci-
nation of cattle with a combination of cathepsin L2
and haemoglobin resulted in a 98% reduction in egg
output, and that the majority of the eggs produced
did not embyonate. This study thus demonstrated
that it is theoretically possible to develop a highly
eﬃcacious vaccine that could also prevent the
contamination of pastures with viable ﬂuke eggs and
thus have a profound blocking eﬀect on disease
transmission.
IMMUNE MECHANISMS OF VACCINE
PROTECTION AGAINST LIVER FLUKES
Although quite a number of vaccine trials have been
carried out by various research groups, no consensus
on the factors required for immunological protection
has emerged. Most immunological analysis has fo-
cused on antibody isotypic responses due to the
earlier lack of reagents for cytokine analysis and,
hence, protective cellular components can only be
inferred. Recent advances in the analysis of ruminant
cytokines should provide the tools to generate more
informative data on the immunological phenotype in
naturally-infected and vaccinated animals (for ex-
ample see Hein et al. 2004) which will be critical to
the design and implementation of future vaccine
formulations.
Neither sheep nor cattle develop strong immunity
to infection with F. hepatica or to subsequent
re-infections (Mulcahy, Joyce andDalton et al. 1999;
Hoyle et al. 2003). Moreover, unlike for other
helminth infections such as schistosomes, hook-
worms and lungworms, vaccines using irradiation-
attenuated larvae do not induce protective immune
responses (irradiatedmetacercariae ofF. hepatica can
survive in the host for up to 28 days but do not
develop beyond 10 day-old immature ﬂukes.) The
studies of Piedraﬁta et al. (2000, 2001) suggest that
the lack of resistance in ruminants is related to the
inability of their macrophages to produce nitric
oxide. Peritoneal lavage cells (mainly macrophages)
obtained from rats, which exhibit high levels of re-
sistance to ﬂuke re-infection, can bind to antibody-
coated newly excysted juveniles (NEJ) in vitro and
induce killing by producing high levels of reac-
tive nitrogen species. In contrast, macrophages of
Merino and Indonesion Thin Tailed (ITT) sheep
did not produce reactive nitrogen species and failed
to kill antibody-coated NEJ, regardless of whether
the source of antibody was infected rats or sheep.
Collective data from studies in ruminants indicate
that liver ﬂukes elicit immune responses involving
the typical hallmarks of the Th2-type, namely
eosinophilia, IgE and the production of IgG1 anti-
body isotypes (Mulcahy et al. 1999; Estes and
Brown, 2002). The current general belief is that hel-
minths can withstand the onslaught of components
of the Th2 arm of the host immune response and that
these responses cause pathological damage to the
host that is tolerated over a long and sustained
period (Pearce and MacDonald, 2002). Migrating
and adult F. hepatica not only secrete molecules that
induce Th2 responses but also others, including
cathepsin L proteases, that appear to actively down-
play Th1 responses (O’Neill et al. 1999b, 2001).
Once the ﬂukes reach the bile ducts of their host, a
site that is considered to be immunologically safe,
they can survive for many years. However, being
blood feeders, they still have contact with the cir-
culation and secrete antigens from their guts that
may be involved in maintaining the Th2-polarised
immune response during chronic fasciolosis (Dalton
et al. 2003b).
A consistent feature observed in vaccine trials
with cathepsin L proteases is the correlation
between antibody isotypic responses and protection.
Naturally-infected animals elicit high IgG1 antibody
titres, which are controlled by the Th2 cytokine IL4,
but little or no IgG2. In contrast, vaccinated animals
elicited both IgG1 and IgG2. Moreover, in trials
involving both cattle and sheep, the titre of IgG2
antibodies generated directly correlated with the
ﬂuke burden of animals within vaccinated groups i.e.
those animals with the lowest liver ﬂuke numbers
exhibited the highest IgG2 levels. Adjuvant such a
Freunds’ incomplete adjuvant which do not induce
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high titres of these antibodies do not induce signiﬁ-
cant protection (Mulcahy et al. 1998, 1999; Dalton
et al. 2003b). The interpretation is that cathepsin L
vaccines induce Th1 or mixed Th1/Th2 responses
with mixed antibody isotypes that bind and inacti-
vate the parasite enzymes and hence block parasite
migration, feeding and the abilty to skew the host
immune response to a fully-polarised Th2-type. The
level of enzyme inactivation, therefore, depends on
the total antibody titre induced by the vaccines but
in particular IgG2. IgG2 antibodies may be involved
in direct enzyme inactivation but may be more
detrimental to the parasites since these are also ef-
ﬁcient activators of complement and phagocytosis by
macrophages (Corbeil, 2002; Crawley and Wilkie,
2003). While sheep macrophages do not produce
nitric oxide following binding to sera from infected
animals (largely IgG1) (Piedraﬁta et al. 2001) they
may become activated in the presence of IgG2.
Other eﬀector cells such as eosinophils and
neutrophils may contribute to the killing process of
already damaged ﬂukes. Although no diﬀerence in
the level of eosinophilia between protected and
cathepsin L-vaccinated animals is observed, a pro-
tective role for these cells cannot be excluded
since their activation status was not examined.
Meeusen and colleagues have proposed that ‘acti-
vated’ eosinophils are responsible for the elimination
of infectiveHaemonchus contortus larvae in protected
sheep (Meeusen and Balic, 2000).
Isotypic analyses were not reported for the FABP
and leucine aminopeptidases and immunological
correlates of protection are therefore still unknown.
In the latter case, enzyme-inhibitory antibodies
have been implicated in the protective responses
and killing may be thus solely due to blocking of
nutrient uptake. GST vaccines formulated in
Freund’s Complete Adjuvant induced both IgG1
and IgG2 isotypes but correlations between the re-
activity of these antibodies to native GST and pro-
tection were not reported. Responses to overlapping
peptides representing linear epitopes were analysed
but revealed no correlation with protection (Spithill
et al. 1999a). Since GST formulated in QuilA/SM
gave the most consistent, albeit variable, protection
in cattle it would be worthwhile investigating the
type of responses generated with this adjuvant.
Lessons we learn regarding immunological re-
sponses following natural infection and vaccination
with F. hepatica cannot be applied directly to
F. gigantica. Merino breeds are susceptible to infec-
tion with F. gigantica whereas ITT show high levels
of resistance. In this case, susceptibility to infection
in Merino sheep was positively correlated with the
induction of IgG2 isotypes, the opposite to that ob-
served in F. hepatica infections of sheep. Correlates
of protection in ITT are Th2 markers including
higher levels of eosinophils, IgM, IgG1 and IgE
(see Meeusen and Piedraﬁta, 2003) and suggest
that F. hepatica and F. gigantica have diﬀerent im-
munomodulation and immunoevasion strategies.
Moreover, biochemical analyses show that the para-
sites express diﬀerent levels of anti-oxidants, such as
glutathione-S transferase/peroxidase, that may pro-
tect them to diﬀerent levels from reactive oxygen
intermediates released by host immune eﬀector cells,
particularly macrophages (Meeusen and Piedraﬁta,
2003). Zhang et al. (2004a, b, 2006) showed that
Bellilois male sheep are more susceptible to infection
with F. hepatica compared to F. gigantica (infection
rates of 18.7% and 5.4% following an infection dose
of 250 metacariae of each parasite) ; they concluded
from their immunological analysis that humoral and
eosinophil/cell mediated responses to F. gigantica
were greater and, hence, more protective. The
take-home message for vaccine developers is that
F. gigantica homologues of antigens with protective
properties against F. hepatica may not neccessarily
protect against F. gigantica or, at the very least, will
require presentation in a diﬀerent adjuvant formu-
lation or administration regime.
HOW DO WE GO FORWARD WITH LIVER
FLUKE VACCINES?
The spread of fasciolosis in Europe, the appearance
of triclabendazole-resistant liver ﬂukes and its
emergence as an important zoonosis of humans have
led to an increased interest in this disease. Interest
is not conﬁned to academia but is also developing in
the animal health industrial sector, not only because
of tighter regulations and costs surrounding drug
development and commercialisation, but also be-
cause advances in recombinant protein technology
has meant that, in terms of cost of production, vac-
cines can now compete with drugs. However, both
the academic and the industrial community need to
be convinced that vaccines can reach an eﬃcacy that
is ‘commercially-viable’ i.e. can provide a obvious
beneﬁt to farmers who have now become used to, and
even dependent on, highly eﬀective chemical prod-
ucts. As it presently stands, the data derived from
the few antigens described in this review show some
promise but are still at an early-stage level.
The cost and logistics associated with performing
vaccine trials in ruminants has been a major obstacle
for most research teams and, hence, the majority
of vaccine data has been derived from laboratory
models such as rabbits, rats and mice. Laboratory
models may be useful for initial vaccine screening
purposes but results obtained have to be treated with
some caution since each of these models: (1) Show
diﬀerent levels of natural resistance; (2)Use diﬀerent
mediators/mechanisms for resistance; (3) May resist
infection at diﬀerent immunological compartments
e.g. rats at both the intestine and liver whereas mice
show no resistance at either; (4) Diﬀer in their
capability of withstanding the pathology of infection
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e.g. mice will die within 28 days following infection
of more than two metacercariae, whereas rats and
rabbits will survive infections of 50 metacercariae
or more; and (5) Respond diﬀerently to various
adjuvants. Despite these limitations, several vaccine
candidates, such as FABP, cathepsin L and leucine
aminopeptidase, have been shown to induce protec-
tion in both rodents and ruminants. More trials in
ruminants are required to demonstrate that these can
provide consistent protection in the target species.
As pointed out by Meeusen and Piedraﬁta (2003),
the development of a vaccine for any helminth
parasite will depend on a better understanding
components of the protective process including: (1)
Recognition of the antigen; (2) Induction of the
protective immune phenotype; and (3) Activation of
appropriate immune eﬀector mechanisms. Un-
fortunately, we have not gathered suﬃcient data on
the present vaccine candidates to identify the cellular
components and their means of protection, and this
must be of high priority in future studies. Studies on
natural immune responses in sheep and cattle, which
are Th2-driven and non-protective compared with
vaccine-induced protective responses, are imperative
to elucidate the mechanism of activation and propa-
gation of cellular and soluble immune factors. If
vaccine-induced protection is dependent on inducing
factors not normally induced by natural infection, for
example a mixed Th1/Th2 response as indicated by
the studies with cathepsin L vaccines (Mulcahy et al.
1998, 1999; Dalton andMulcahy, 2001; Dalton et al.
2003b), then it will be necessary to determine the
longevity of this ‘altered’ immune response in the
face of continual exposure to Th2-inducing natural
infection (and other Th2-inducing pathogens). Also,
some vaccines may not be naturally immunogenic
(often referred to as hidden antigens) and will not
receive boosting following natural infection regard-
less of the type of immune response induced by the
vaccine. In both cases, repeat vaccinations (six-
monthly or yearly) may be required to prevent
natural infection reversing or even suppressing the
vaccine eﬀect. In contrary cases, for example the
leucine-aminopeptidase vaccine, it may be suﬃcient
to induce high enzyme-blocking antibody titres of
any isotype, and boosting of antibody responses by
natural infection may maintain or even enhance
protection.
To date there has not been a report of a successful
ﬁeld trial of any liver ﬂuke vaccine. Because of the
obvious diﬀerences in parasite exposure in exper-
imental vaccine trials and in ﬁeld conditions (not to
mention possible genetic variation in wild parasites
compared to laboratory strains) it cannot be pre-
dicted howwell the current vaccine candidates would
perform in the ‘real situation’ and under variable
environmental and disease-transmission pressures.
Moreover, the immune responses of sheep and
cattle (and other species) to natural infection and to
vaccination will clearly diﬀer and vaccine design and
formulation will likely need to be unique to each
species. An additional challenge to overcome will be
internal variation in immune responses due to host
genetics that may confer some breeds with a better
ability to develop protective responses to some an-
tigens and/or to certain formulations. To surmount
these obstacles it is likely that the ﬁnal liver ﬂuke
vaccine will be composed of several protective anti-
gens that elicit protection through diﬀerent
mechanisms, involving both antibody and cellular
components. The mixture of such a cocktail vaccine
could include the antigens described in the present
review and a critical next stepwould be to empirically
assess combinations of these in sheep and cattle.
There is an expanding range of adjuvants, com-
mercially available and reported in the litera-
ture, with various abilities to activate diﬀerent
components of the immune system. Arriving at the
appropriate adjuvant for commercialisation will re-
quire systematic testing in trials that investigate site
of injection and timing between vaccinations.
Ultimately requirements and restrictions related to
on-farm/animal-side vaccine use will dictate that
vaccines be prepared in easily deliverable, stable
adjuvants in a user-friendly way and convenient time
(e.g. injectable, given twice within a four-week per-
iod with possible, as mentioned above, six-monthly
or yearly boosting).
The development of a liver ﬂuke vaccine for ani-
mals could play a major role in eliminating human
infection in endemic regions. Human disease is
always associated with endemic animal disease and,
therefore, vaccination of animals (including reservoir
hosts) to prevent infection and block disease trans-
mission should be incorporated alongside the ad-
ministration of chemotherapy to humans in any
future control programme. Because the regions
where human fasciolosis is endemic tend to be rela-
tively small and geographically conﬁned e.g. the
Andean altiplano, the Nile Delta or the northern
provinces of Iran, the chance of a well-designed
control programme of having success is high. Curtale
et al. (2005) recently reported a successful inter-
vention programme in the Nile Delta, Egypt, that
involved screening almost 36 000 schoolchildren
between 1998 and 2002 and treating 1280 cases of
fasciolosis with triclabendazole (Egaten). The result
of this ‘targeted selective chemotherapy’ in this en-
demic area was the reduction of prevalence from
5.2% to 1.2%, in addition to lowering infection in-
tensity. This study demonstrates that, with the
proper local support, a similar programme could be
successful if introduced in other endemic regions and
it also raises the possibility of greater success if a
parallel animal vaccination programme was put in
place. Since fasciolosis is a food-borne disease edu-
cational programmes also have a major role to
play, although the likelihood of changing current
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agricultural traditions and eating habits in regions
that are generally under-developed and rural is slim.
Considering that human behaviour is diﬃcult to
change Macpherson (2005) suggests that for edu-
cational programmes to succeed the correct message
regarding how disease is spread needs to be delivered
to the at-risk group, and a direct link between the
cause of disease and its resulting pathogenesis has to
be made. In summary, a good control programme
will require chemotherapy, vaccination, education
and local government support.
CONCLUSION
While progress in vaccine development for two of the
most important ﬂatworm taxa, schistosomes and
fasciolids, has been slow recent results are optimistic
for the future implementation of ﬁrst generation
recombinant vaccines. The current schistosome and
fasciolid vaccine candidate antigens and prototype
vaccine formulations induce signiﬁcant levels of
protection in animals using the standard readouts
of reduced worm burden or egg production and
viability but are not yet ready for application in the
ﬁeld. It is important to continue to identify new
target antigens and to explore alternative vaccination
strategies to improve vaccine eﬃcacy. One approach
to progressing the challenge is through the estab-
lishment of an antigen discovery pipeline. Molecules
containing signal peptides and signal anchors as
predictors of excretory-secretory products, includ-
ing enzymes, and components exposed on the
schistosome epithelial surfaces (including receptors)
that interact directly with the host immune system,
are relevant targets for study. Mining, functional
annotation and gene ontology categorisation of the
greatly expanded genomic databases (Dalton et al.
2003a ; Hu et al. 2003; Verjovski-Almeida et al.
2003) has allowed identiﬁcation of potential vaccine
candidates such as secreted toxins/allergens, cell
surface adhesion receptors, surface-exposed mem-
brane proteins, receptors for host factors and surface
exposed enzymes. Whereas the prediction of vaccine
potency from sequence information is somewhat
speculative, immunological and vaccine/challenge
studies in animal models should conﬁrm the identity
of key antigens for further study. Additional vaccine
candidates will also likely be discoverd by proteomics
(Jeﬀeries et al. 2001; Curwen et al. 2004, 2006;
Cheng et al. 2005; van Balkom et al. 2005; Knudsen
et al. 2005) and microarrays (Fitzpatrick et al. 2004,
2005; Vermeire et al. 2006; Chai et al. 2006; Gobert
et al. 2006; Moertel et al. 2006) approaches.
Diﬃculties in obtaining good expression levels and
scaling up production according to GLP/GMP
standards of the limited number of antigens selected
have turned out to be another major obstacle.
Feasibility of large-scale production should be a
prime selection criterion in assessing the vaccine
candidacy of schistosome and fasciola antigens
(Dalton et al. 2003a ; Bergquist et al. 2005). In ad-
dition, the selection of a suitable adjuvant to aid in
the stimulation of the appropriate immune response
is a critical step in the path to the development and
employment of a successful transmission-blocking
veterinary vaccine for S. japonicum, F. hepatica and
F. gigantica.
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